


# REAL-WORLD PERSISTENCE WITH DOLUTEGRAVIR/LAMIVUDINE VERSUS BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE AMONG HUMAN IMMUNODEFICIENCY VIRUS PATIENTS.

L. Martín Zaragoza<sup>1</sup>, J. Sánchez-Rubio Ferrández<sup>1</sup>, A. Onteniente González<sup>1</sup>, M. Gómez Bermejo<sup>1</sup>, A. Alcántara Prado<sup>1</sup>, L. Carmona Juárez<sup>1</sup>, S.J. Rodríguez Álvarez<sup>2</sup>, A. Monereo Alonso<sup>2</sup>, T. Molina García<sup>1</sup>.  
Pharmacy Service<sup>1</sup>. Internal Service H.U de Getafe, Madrid (Spain)<sup>2</sup>

## Background and Importance

Persistence can provide information on the comparative effectiveness, durability and tolerability in real-world patient populations.



Little is known about comparative persistence of dolutegravir/lamivudine (DTG/3TC) and bicitegravir/emtricitabine/tenofovir-alafenamide (BIC/FTC/TAF).

## Aim and Objectives



To compare persistence between two preferred antiretroviral therapies and analyze reasons for discontinuation.

## Materials and Methods



Retrospective  
Non-interventional  
Longitudinal



All HIV patients over 18 years treated with DTG/3TC or BIC/FTC/TAF



Start of treatment – end observation period (March 2022)

Persistence was also calculated as a dichotomous variable at the conclusion of the first year of therapy. Permissible gap was 90 days.



Covariates collected from medical record were:

- Age, gender
- Viral load (VL), CD4 count
- Number of previous antiretroviral medications
- Charlson comorbidity index
- Medication Possession Ratio (MPR)

- ✓ Persistence after first year was compared using the  $\chi^2$  test.
- ✓ **Kaplan-Meier survival analysis** was performed and differences were evaluated using the **log-rank test**.
- ✓ Adjusted risk of discontinuation was assessed with **Cox Proportional Hazard models**.
- ✓ **Significance level was 0.05.**

## Results

**362**

- **79.2% were male**
- 5.2% were naive
- Age (mean±SD) was 47±12 years
- 91.2% had VL<200 copies
- 10.1% CD4<200/ml
- **Number of previous treatments was 3.5±2.6.**
- MPR was 95.4±11.1.
- Charlson comorbidity index was 1±1.66.
- **49.2% were treated with BIC/FTC/TAF**

Persistent after the first year  
DTG/3TC → 97.8%  
BIC/FTC/TAF → 89.7%

[OR= 5.1  
(CI95% 1.7-15.6)  
p=0.002

Persistence with **DGT/3TC** was **1.231 days**  
Persistence with **BIC/FTC/TAF** was **980 days**  
**p=0.001**

Cox-model adjusted HR was 2.5 (IC95% 0,5-12;p=0.26).

The main reasons for discontinuation			
BIC/FTC/TAF		DTG/3TC	
n = 9	tolerability/toxicity	n = 1	toxicity
n = 3	death	n = 1	death

## Conclusion and Relevance

- ✓ **More patients on DTG/3TC were persistent after the first year compared to BIC/FTC/TAF** (however, there were no differences in overall persistence in covariate-adjusted analysis)
- ✓ **Main reason for BIC/FTC/TAF discontinuation was tolerability/toxicity**

